A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Clinical trial NCT04278144 · TERMINATED

Trial details

NCT number: NCT04278144
Sponsor: Bolt Biotherapeutics, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Colorectal Cancer HER2-positive Gastroesophageal Cancer HER2-positive Endometrial Cancer

Start date: 2020-02-24
Primary completion: 2024-12-10
Enrollment: 175

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.